Skip to content
OpenCapital
Get started

Cytek Biosciences, Inc. CTKB Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value at other companies

Ametek logo
AmetekAME
$154.9M+32.2%
MSCI logo
MSCIMSCI
$2.32M—
Rockwell Automation logo
Rockwell AutomationROK
$144M+30.3%
Lightwave Logic, Inc. logo
Lightwave Logic, Inc.LWLG
$27.56M+2,406%
The Travelers Companies logo
The Travelers CompaniesTRV
$586M-7.7%
General Dynamics logo
General DynamicsGD
$817M+57.7%

Other financials

Income statement

See full
Revenue$44.1M+6.5%
Gross profit$21.3M+5.4%
Operating income-$18.5M-23.3%
Net income-$18.9M-65.5%
EPS (diluted)-$0.15-66.7%

Balance sheet

See full
Cash & equivalents$31.8M-66.6%
Total debt$16.8M+40.9%
Total equity$327.6M-13.7%
Total assets$449.1M-6.9%

Cash flow

See full
Operating cash flow-$2.7M-2,089%
CapEx$2.2M+155%
Free cash flow-$4.9M-403%

Valuation

See full
Market cap$577.27M+54.5%
Enterprise value$562.23M+93.7%
P/S2.8×+0.9×

Profitability

See full
Gross margin51.7%-3.2pp
Operating margin-21.5%—
Net margin-36.2%—
FCF margin-6.2%-15.1pp

Returns & leverage

See full
Return on equity-20.9%—
Debt / equity0.1×0.0×
Current ratio4.7×-0.9×

Where this comes from

Reported directly by Cytek Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.

The official record: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytek Biosciences, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytek Biosciences, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?
Cytek Biosciences, Inc. (CTKB) reported share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value of $3.77M in Q1 2026.